BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, May 24, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Other news to note for March 4, 2021

March 4, 2021
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abiomed, Accessdx, Biointellisense, C2i Genomics, Cloudbreak Health, Genetic Technologies, Infinity Biologix, Medquest Pharmacy, Qna Dx, Gravity, Kits, Medicortex, Philips, Qiagen, Relay Medical, Revolugen, Sonde, Swift, Zepp.
Read More
Cuba mask and syringe

Cuba’s Soberana 02 SARS-CoV-2 vaccine candidate moves to phase III trials

March 4, 2021
By Sergio Held
CAJICA, Colombia – Cuba’s Center for the State Control of Drugs, Equipment and Medical Devices gave the green light March 3 for phase III trials of a domestically developed COVID-19 vaccine candidate, even though very little peer-reviewed information has been published about it.
Read More
Regulatory front

FDA guidance addresses COVID-19 supply constraints

March 4, 2021
By Mari Serebrov
The latest global regulatory news, changes and updates affecting biopharma, including: Australia eases substitution requirements; Guidance details fast-tracking modified vaccines.
Read More

Regulatory actions for March 4, 2021

March 4, 2021
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Kronos, Nervgen, Nicox, Novadip, Ocumension, Pfizer, RDIF, Regeneron, Sanofi.
Read More

Other news to note for March 4, 2021

March 4, 2021
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Akari, Aptamer, Arch, Astrazeneca, Autifony, Bellicum, Biogen, Boehringer, Claritas, Conserv, Curevac, Dicerna, Etherna, Foresee, Intas, GC, Hookipa, Juvenescence, Lipocine, Lumos, Merck, Mitsubishi Tanabe, Moderna, Novartis, Oncology Pharma, Pandion, Portage, Roche Silo, Sunshine, Therapeutic Solutions, Tonix.
Read More

In the clinic for March 4, 2021

March 4, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abivax, Allarity, Apollomics, Cyclo, Dicerna, Diamyd, Dnatrix, Galapagos, Landos, Lilly, Mallinckrodt, Provention, Ridgeback, Roche, TFF, VBL, Ysopia.
Read More
Brazilian flag

Study identifies Brazil SARS-CoV-2 variant that can evade protective immunity

March 3, 2021
By Nuala Moran
LONDON – The SARS-CoV-2 variant of concern that caused a wave of infection in Manaus, Brazil, in December and January has been found to be both more transmissible and to evade immunity conferred by prior natural infection with the virus. A combined Brazil/U.K. genome sequencing and epidemiological study found the variant, called P.1., is between 1.4 and 2.2 times more transmissible than earlier lineages, and can evade 25% to 61% of the protective immunity elicited by previous infection.
Read More

Regulatory front for March 3, 2021

March 3, 2021
The latest global regulatory news, changes and updates affecting medical devices and technologies, including: GAO reviews FEMA's pandemic supply chain management efforts; Testing lab owner sentenced to three years; Health Canada renews interim order for importation of devices; FDA: claims of registration certificates may be misleading; MDCG issues gap guidance pending Eudamed completion; FDA seeking nominations for advisory committee.
Read More

Other news to note for March 3, 2021

March 3, 2021
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Bioivt, Biolase, Chromacode, Combinati, Contipi Medical, Dignitana, Disney, Edap, Ers Genomics, Global Wholehealth Partners, Indegene, Innerscope Hearing Technologies, Lumos Diagnostics, Medi-Launch Partners, Nexgel, Northern Diagnostics, Nurokor, Ovia Health, Philips, Rewalk Robotics.
Read More

WTO head: Vaccine companies must license sites in emerging countries

March 3, 2021
By Mari Serebrov
As the World Trade Organization (WTO) debate intensified this week over a demand to waive patent protections for COVID-19 vaccines and therapies, the group’s new director-general, Ngozi Okonjo-Iweala, urged members to “walk and chew gum” at the same time by working with “companies to open up and license more viable manufacturing sites now in emerging markets and developing countries. We must get them to work with us on know-how and technology transfer now.”
Read More
Previous 1 2 … 271 272 273 274 275 276 277 278 279 … 552 553 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 22, 2026.
  • Acid alpha-glucosidase molecular structure isolated on black

    ‘Detargeted’ targeted gene therapy improves activity in Pompe

    BioWorld
    A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
  • Roche reports new TREM2 agonists

    BioWorld Science
    F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
  • Genescience presents STAT6 degrader for atopic dermatitis

    BioWorld Science
    Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
  • Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis

    BioWorld Science
    Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing